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Abstract
Viral infections have been implicated in the pathogenesis of multiple sclerosis. Epstein-Barr virus (EBV) has frequently been
investigated as a possible candidate and torque teno virus (TTV) has also been discussed in this context. Nevertheless,
mechanistic aspects remain unresolved. We report viral replication, as measured by genome amplification, as well as
quantitative PCR of two TTV-HD14 isolates isolated from multiple sclerosis brain in a series of EBV-positive and -negative
lymphoblastoid and Burkitt’s lymphoma cell lines. Our results demonstrate the replication of both transfected TTV genomes
up to day 21 post transfection in all the evaluated cell lines. Quantitative amplification indicates statistically significant
enhanced TTV replication in the EBV-positive cell lines, including the EBV-converted BJAB line, in comparison to the EBV-
negative Burkitt’s lymphoma cell line BJAB. This suggests a helper effect of EBV infections in the replication of TTV. The
present study provides information on a possible interaction of EBV and TTV in the etiology and progression of multiple
sclerosis.
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Introduction
The pathogenesis of multiple sclerosis (MS) is probably triggered
by a combination of genetic and environmental factors [1–5].
Frequent childhood infections, lower socioeconomic status and
higher sibling exposure lead to a lower MS prevalence, remarkably
similar to observations made in childhood leukemias [6]. Children
experiencing viral infections later in life are at risk for developing
this disease [1,3,4,7–9]. More sensitive detection methods have
enabled earlier recognition of pediatric MS, leading to an
estimated 2–5% of cases developing before the age of 16 years
[10–12]. The disease has even been diagnosed in children between
2 and 5 years of age [13,14].
Several viruses have been considered to be involved [3,4].
Morbilli- and coronaviruses [15,16] which, similar to Theiler’s
murine encephalomyelitis virus (TMEV) in mice [3,17], induce
demyelinating disease in their natural hosts. JC polyomavirus was
also proposed, but is presently considered to be a bystander in MS
[18,19]. A number of herpesviruses have been investigated as
etiological factors for MS. Activation of varicella zoster virus (VZV)
was demonstrated during exacerbations [20,21]. An upregulation
of the endogenous retroviruses HERV-H and HERV-W tran-
scription was mediated by herpesviruses Herpes simplex-1 (HSV-
1), human herpesvirus-6 (HHV-6) and VZV [22,23]. A more direct
role for HHV-6 in MS was suspected [24,25], but was subsequently
questioned because no difference was observed in the HHV-6
prevalence between cases and controls [26,27], although its
possible role prior to onset of disease was not excluded [28].
HHV-6 glycoprotein expressed on the surface of infected T
lymphocytes allows for its fusion to oligodendrocytes and astrocytes
expressing the CD46 receptor which is necessary for viral entry
[29]. Cross-reaction of HHV-6 and myelin has also been reported
[30]. Individuals with a history of EBV-induced infectious
mononucleosis are at 2- to 3-fold increased risk of developing
MS [31,32] in contrast to the risk being extremely low in EBV-
negative individuals [33]. Elevated EBV antibody titres have been
associated with the onset of MS [4,9,10,12,34–36], but not during
the course of disease [37] and whether active EBV infection
actually plays a role in ongoing MS disease is controversial [38–
40]. Mechanistic aspects through which EBV infections may
participate in the pathogenesis of MS also remain elusive, despite
the compelling epidemiological data available [32,33].
Infection-induced molecular mimicry has been implicated in
several autoimmune diseases including MS [41–44]. CD4
+T
lymphocytes responding to the latent EBV nuclear antigen-1
(EBNA-1) are increased in patients with MS [45,46] and these cross
react with myelin antigens [47]. Our previous study [43]
demonstrated the response of clonally expanded CD4
+T cells
isolated from an MS patient to the poly-arginine motif present in
theopenreadingframe1(ORF1)ofcertaintorquetenovirus(TTV)
types. Serum samples from this patient, taken during exacerbation
and 24 months later, harboured TTV DNA sequences. In addition,
we demonstrated TTV DNA in 6 of 13 brain samples, 12 from MS
brain and one in HHV-6 encephalitis brain.
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involved in their replication are not understood. TTV was first
identified in a Japanese patient suffering post-transfusion hepatitis
of unknown etiology [48]. A multitude of TTV genotypes with
marked genetic heterogeneity has subsequently been identified
[49]. Primary infection occurs very early in life with 47,6% of
children infected with at least 3 TTV types at 6 months of age and
93% at 1 year of age [50,51]. Their genomic diversity and
ubiquitous prevalence have posed main obstacles in attempts to
define a role for TT viruses in the pathogenesis of disease
[49,52,53]. TTV DNA has been demonstrated in many organs
and tissues [43,54–56]. Peripheral blood act as reservoir for TT
viruses [57,58] and replicative viral DNA has been demonstrated
in bone marrow cells and the liver [59,60]. Other reports have
implicated TTV infections in autoimmune diseases [52,61–63].
Influences of host-dependent factors, genotype predilection or
environmental triggers on the long-term replication of TT viruses
have not been investigated. Short term replication and transcrip-
tion were described in cell lines of diverse origins [64–66]. We
recently reported long-term replication of TT viruses with the
concomitant formation and independent replication of subviral
mTTV (consisting of 10–20% of the mother genome) [67]. We
evidenced intracellular viral-like particle formation 7 days after
transfection of the TTV-tth8 full-length genome into an Hodgkin’s
lymphoma cell line L428 [65].
Studies in the past concentrated on single virus infections as
etiological factors of MS, whereas interactions between viruses in
its pathogenesis have not been approached. Herpesviruses have
been known to induce amplification of other viral genomes, as well
as cellular sequences [68–72]. EBNA-1 enhances replication of
Hepatitis C virus (HCV) [73]. The current study analysed the
question whether EBV can stimulate or induce TTV replication in
vitro. We have isolated a series of full-length TTV genomes from
diseased brain of MS patients [67]. We transfected two of these
TTV isolates into EBV-carrying cell lines. Two EBV-negative cell
lines were used as controls. Quantitative PCR analyses clearly
demonstrate a helper effect of EBV on the replication of the TTV
genome. These results provide additional information for linking
viral infections to the pathogenesis of MS.
Results
In vitro replication of TTV-HD14b and TTV-HD14c
We subsequently demonstrated the helper-dependent long-term
replication and propagation of 12 TTV isolates in the 293TT cell
line harbouring SV40 large T-antigen [67]. In the present study
we analysed whether EBV is also able to exert a helper function for
the replication of TTV. We included Burkitt’s lymphoma cell lines
both positive (P3HR-1, BJAB/EBV, Ramos/EBV) and negative
for EBV (BJAB, Ramos), an EBV-immortalized B cell line (ND1)
from an MS patient and an EBV-producing B cell line (B95-8).
Replication of TTV-HD DNA was confirmed in all tested cell
lines by long distance PCR on total cellular DNA. Long distance
PCR was performed using back-to-back primers specific for
amplifying the full-length genomes of TTV-HD14b and TTV-
HD14c. Examples are presented in Figure 1A. Results were
comparable between TTV-HD14b and TTV-HD14c and repli-
cation was measured up to day 21 after transfection in all cell lines.
Replication was also confirmed by electron microscopy (Figure 1B).
Replication of TTV-HD14b and TTV-HD14c is increased in
the presence of EBV
Having demonstrated virus replication after transfection of
TTV-HD14b- and TTV-HD14c-full-length genomes into EBV-
positive and -negative cell lines, we quantified the level of TTV
replication by real-time PCR. Viral DNA was normalized against
the housekeeping gene HMBS and relative quantification was
calculated using the EBV-negative cell line BJAB as calibrator. All
measurements were performed for each time point when cells were
harvested. We used two independent primer sets per isolate for the
detection of both TTV-HD14b and TTV-HD14c. Two isolates of
TTV-HD14 were included in this study in order to avoid possible
variations which may result from differences in the TTV genome
organization. Primers and probes are listed in Table 1.
The quantitative analyses performed with one set of primers
and probe for TTV-HD14b and TTV-HD14c are shown in
Figure 2 (A and B). Overall, TTV-HD replication was increased
up to day 21 in all cell lines tested when compared to viral
replication in BJAB. Comparable results were obtained with the
second primer pair and probe selected for this study (data not
shown) and a similar pattern of amplification was obtained with
different biological replicates. Untransfected control and non-
template control samples remained negative in all experiments.
The presence of EBV in cell lines BJAB/EBV, P3HR-1 and
Ramos/EBV resulted in elevated levels of TTV-HD14b and
TTV-HD14c DNA replication. Replication of both TTV-HD14
isolates was significantly higher (p,0.05) in all cell lines when
compared to BJAB at each time point of evaluation (Figure 2).
From day 7 onwards, a higher level of TTV-HD14b replication
(Figure 2A) was noted in the BJAB cell line converted to EBV-
positivity, than in the other cell lines. Viral levels seemed to
increase early after transfection, after which it levelled off.
Replication of TTV-HD14b versus TTV-HD14c varied signifi-
cantly (p,0.05) in each cell type, except for day 17 after
transfection where replication differences between isolates in
Ramos/EBV and B95-8 were not statistically significant, as well as
day 3 where replication of the two TTV isolates did not differ
significantly. TTV-HD14c replication in ND1 (EBV-immortalized
B cells from an MS patient) (Figure 2B) seemed to be stable over
time in comparison to a decrease for TTV-HD14b replication in
these cells. An initial increase in B95-8 decreases more rapidly for
TTV-HD14c than for TTV-HD14b. TTV replication behaviour
in the EBV-positive Ramos/EBV cell line was surprising. The
increased TTV-HD14b replication in Ramos/EBV versus Ramos
cells was statistically significant (p,0.0001) up to day 14, where
after TTV-HD14b replication in Ramos cells exceeded that in
Ramos/EBV cells (days 17 and 21). TTV-HD14c replication in
Ramos/EBV cells increased from day 3 to day 17, with levels
reaching statistical significance for day 3 to 7 (p,0.0001), but not
for days 14 and 17. Replication on day 21 was similar in both
isolates with higher replication in Ramos than in Ramos/EBV
cells. A previous report did not detect any difference in the level of
permissiveness for an HSV-1 infection between Ramos and EBV-
converted Ramos/EBV cells [74].
The enhanced replication of TTV-HD14b and TTV-HD14c
in the presence of EBV is independent of the EBV copy
number
Having measured varying levels of TTV replication in the
respective EBV positive cell lines, we quantified the EBV DNA to
determine whether EBV copy number exerted an influence. Real-
time quantitative PCR was performed at all time points (day 3–21
post transfection) and in all cultures transfected with both TTV
genomes using DNA from an EBV-harbouring (2 copies/cell) cell
line Namalwa as standard curve [75]. A representative example of
EBV copy number/cell at day 14 post-transfection of TTV-
HD14c is presented in Figure 3. The EBV copy number in the
P3HR-1 cell line was 583 copies/cell, whereas B95-8 cells
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habor only 10 EBV copies/cell despite the high levels of TTV
amplification. The lowest EBV copy number was found in
Ramos/EBV containing from 2 EBV copies/cell. From this
analysis we can conclude that although the presence of EBV seems
to enhance replication of TTV-HD DNA, the EBV viral copy
number does not reflect the differences in replication level between
cell lines.
EBV production measured by gp350/220 expression is
consistent with the EBV copy number and does not
correlate with TTV replication
Quantification of EBV DNA genome does not provide
information regarding the intracellular activity of the EBV
DNA. P3HR-1 and B95-8 are well-characterized cell lines in
which EBV production has been reported [76,77], whereas EBV
viral capsid antigen (VCA) and synthesis was demonstrated in the
Figure 1. In vitro replication of TTV-HD14b and TTV-HD14c as measured by long-PCR amplification. (A) PCR amplification of full-length
TTV-HD14b in P3HR-1, BJAB, BJAB/EBV and full-length TTV-HD14c in ND1 and Ramos/EBV cell lines. Days after transfection are indicated. M - DNA size
marker, C1 - untransfected cells, C2 - untransfected cells with nucleofector solution, + - positive control for long PCR amplification consisted either of
re-ligated TTV-HD14b or TTV-HD14c mixed with Ramos cell line DNA. (B) Electron micrograph of B95-8 cells 3 days after transfection with linearized
TTV-HD14b DNA. TTV-like particles can be seen within the nucleus of a cell. EBV particles are indicated by short arrows. Bar=250 nm.
doi:10.1371/journal.pone.0032160.g001
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less clear in the Ramos/EBV cell line and unknown for the ND1
cell line. We therefore quantified the EBV envelope glycoprotein
gp350/220 mRNA as marker for EBV lytic activity in all EBV
positive cell lines used in this study [79]. The results obtained
showed a similar pattern as the EBV genome quantification. For
comparison of the EBV DNA copy number, the RNA quantifi-
cation presented in Figure 3 represents day 14 after transfection of
TTV-HD14c. B95-8 and P3HR-1 showed the highest EBV-
gp350/220 copy numbers of 48268 and 25018 copies/5 ng of
total cellular RNA, respectively (Figure 3). ND1 cells harboured
8141 EBV-gp350/220 copies/5 ng RNA, followed by BJAB/EBV
and Ramos/EBV with 965 and 240 copies/5 ng total RNA,
respectively. Consistent results were obtained with both TTV
isolates and with different biological replicates. Thus, EBV was
replicating (as measured by gp350/220 gene transcription) in all
EBV-positive cell lines used in this study, but this productivity did
not necessarily relate to the EBV copy number/cell. The level of
this EBV activity however does not seem to influence the level of
TTV-HD replication.
Discussion
We have transfected the full-length genomes of two TT viruses
isolated from brain tissue from an MS patient in order to ascertain
first, whether viral replication takes place in different B
lymphocytic and Burkitt’s lymphoma cell lines and, secondly, to
determine whether EBV acts as a helper virus for the replication of
TTV. The results presented here demonstrate replication of both
TTV-HD14b and TTV-HD14c up to day 21 post-transfection.
Overall, we observed that the replication pattern of both TT
viruses is cell-type dependent with higher levels of replication
measured in the EBV positive cell lines, but showing variability in
the DDCt at certain time points (Figure 2). A number of studies
have demonstrated the ability of herpesviruses to induce
amplification of other persisting viral DNA [80]. Several lines of
evidence may indicate the mechanism through which EBV exerts
its helper-function for TTV replication. Our previous study [67]
demonstrated a requirement for a helper-function in the
replication and propagation of a series of TTV isolates in the
293TT cell line which had been constructed to express high levels
Table 1. Primers and probes used.
Primers
a Sequence (59-39)
b Nucleotide position Target
Long-PCR
jt34f-7-F 59-CAATTCGGGCTCGGGACTG-39 216–234 TTV-HD14b
jt34f-8-R 59-CCCCTTGACTGCGGTGTGTA-39 215–196 TTV-HD14b
t3pb-1-F 59-CAATTCGGGCACGGGACT-39 216–233 TTV-HD14c
t3pb-2-R 59-CCCCTTGACTTCGGTGTGAAACT-39 215–192 TTV-HD14c
In vitro transcription
gpU2-BamHI 59-GCAGGATCCAGAATCTGGGCTGG
GACGTT-39
89585–89604 EBV gp350/220
gpL2-EcoRI 59-GCAGAATTCACATGGAGCCCGGA
CAAGT -39
89784–89766 EBV gp350/220
Real-time PCR
qP31-F 59-ACAGACCAATCAGGACCTTCTAC-39 31–53 TTV-HD14b/c
qP133-R 59-CGGACGGGCGAAGAAAAAC-39 133–115 TTV-HD14b/c
qP113-Pr 59-FAM-CTACCATTCGTCCACCGCTGTT
GCTT-39- TAMRA
113–89 TTV-HD14b/c
qP326-F 59-GTGCCAGGTAGAGGGAATCAATG-39 326–348 TTV-HD14b/c
qP430-R 59-GCGAGGAGCAATGCCGTTAAG-39 430–410 TTV-HD14b/c
qP396-Pr 5 -FAM-TCACCACACCCGCAGAAAGCA
GCAT-39- TAMRA
396–372 TTV-HD14b/c
EBV-pol-F 59-CTTTGGCGCGGATCCTC-39 1978–1994 EBV BALF5
EBV-pol-R 59-AGTCCTTCTTGGCTAGTCTGTTGAC-39 2044–2068 EBV BALF5
EBV-pol-Pr 59-FAM-CATCAAGAAGCTGCTGGCGGC
C-39- TAMRA
1998–2019 EBV BALF5
gpU2 59-AGAATCTGGGCTGGGACGTT-39 89585–89604 EBV gp350/220
gpL2 59-ACATGGAGCCCGGACAAGT -39 89784–89766 EBV gp350/220
EBVGPq 59-FAM-AGCCCACCACAGATTACGG
CGGT-39- TAMRA
89761–89739 EBV gp350/220
HMBS-F 59- CAGGACTAATYSAARTCTCTAC -39 3731–3752 HMBS
HMBS-R 59- CCAGAAAACTCACTGATTTCAA- 39 3844–3823 HMBS
HMBS-Pr 5 -FAM-CTTGCTCGCATACAGACGGA
CAGT-39- TAMRA
3759–3782 HMBS
a- F, forward; R, reverse; Pr, probe.
b- Underlined letters indicate restriction sites.
doi:10.1371/journal.pone.0032160.t001
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TT viruses harbours a number of pentanucleotide motifs very
similar to binding sites for SV40 large T-antigen. EBNA-1 is
required for the episomal maintenance of EBV DNA and binds to
the origin of replication in a sequence-specific manner [82].
Cellular transcription and gene expression is also regulated by
EBNA-1 through binding to cellular promoters. Analyses of a large
number of these promoters indicated differences in EBNA-1
binding motifs between those found in the EBV genome and
cellular genome [83], indicating a notion of additional, yet
unidentified, binding sites for EBNA-1. Cellular promoters devoid
of EBNA-1 binding sites may even be upregulated by the mere
presence of EBNA-1 in the cell [84]. Enhancement of HCV
replication by EBNA-1 via a transactivating function has been
demonstrated [73]. Additional investigation is needed to clarify the
mechanism through which EBNA-1 may act to stimulate the TTV
genome. We selected several EBV-positive Burkitt’s lymphoma-
and B cell lines in order to evaluate the TTV-HD14b and TTV-
HD14c replication. All these EBV-positive cell lines contained the
EBNA-1 as evidenced by the quantitative measurement of the
envelope glycoprotein gp350/220 mRNA as marker for EBV lytic
activity (Figure 3). The TTV origin of replication is present in both
TTV-HD14 isolates used in the present study and was not
influenced by other differences between these 2 viral genomes [this
study, 67].
A role for virus infections in the etiology of multiple sclerosis has
repeatedly been investigated [4,36]. A possible role for TTV
infection in autoimmune disease including multiple sclerosis, has
been reported previously [43,52,61–63]. The role of EBV
infections in MS has however been controversial ranging from
failure to demonstrate any presence [38–40,85] to demonstration
of an increased risk for a previous EBV infection [9,86] and
Figure 2. In vitro replication of TTV-HD14b and TTV-HD14c as measured by real-time quantitative PCR. Replication of (A) TTV-HD14b
and (B) TTV-HD14c. qPCR values are expressed in DDCt relative to BJAB (used as calibrator). Shown are mean 695% confidence interval values of
triplicate tests. A significant higher replication level of both TTV isolates was detected in all cell lines when compared to BJAB (p,%0.05).
doi:10.1371/journal.pone.0032160.g002
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MS patients [4,87–91].
Presently, studies on an association between both TTV and
EBV infection in lymphocytes of B-cell lymphoma and Hodgkin’s
lymphoma have been inconclusive [92,93]. An increased permis-
siveness for infection with herpes simplex virus during the first
48 hours of infection has been demonstrated in EBV-converted,
previously negative Burkitt’s lymphoma derived cell lines [74].
Therefore the presence of both TTV and EBV in the same B cell
is feasible. Naive and memory B cells are equally susceptible to
EBV infection [94]. EBV infection may lead to EBV persistence in
B cells providing ground for differentiation into EBV-latently
infected circulating memory B cells [95]. Ectopic follicle-like
structures harbouring B cells, similar to those found in other
organ-specific immune disease, have also been described in the
cerebral meninges of some MS patients [96]. The persistence of
EBV infection, as measured by elevated EBNA-1 antibodies, could
provide a fertile field for the induction of molecular mimicry. It has
been proposed that autoreactive T cells induced by molecular
mimicry may need such a fertile field of persistent viral infection to
become autoaggressive [97]. In vivo clonally expanded CD4
+T cells
isolated from cerebrospinal fluid of an MS patient, responded to a
poly-arginine motif present in TT viruses [43]. The TTV-HD14
isolates used in the present study were isolated from MS brain
tissue. Putative proteins from genes and their transcripts of TTV-
HD14 and its mTTV share similar but sufficiently modified
signature motifs to cellular genes including myelin basic protein
(MBP) (unpublished results). A number of studies have indicated
an elevated myelin specific T cell population in MS patients
[36,47]. We propose the following model for a role of both EBV
and TTV infections as etiological agents in MS: Simultaneous
infection by either TTV or mTTV in EBV-infected memory B cells
leads to persistence of the TTV supported by EBNA-1 expression.
Spontaneous activation of the EBV lytic cycle in such cells could
result in a burst of TTV or mTTV expression and production and
infection of neighbouring cells. TTV autoimmune-reactive
epitopes in turn induce autoreactive T cells [97] reacting against
specific proteins of the TTV-infected cells. This model could
explain the local autoimmune response, the focal nature of MS
lesions and the re-emergence of new foci. We have demonstrated
EBV-helper dependent activation of TTV-HD14 isolated from
MS brain tissue. Ongoing studies are investigating the cross-
reactivity of TTV-HD14 expressed proteins to myelin immune
response.
Materials and Methods
Cell culture
Seven hematopoietic cell lines, either EBV-positive or EBV-
negative, were selected for this study. Burkitt’s lymphoma cell lines
included BJAB and Ramos, both EBV-negative [98,99] and
P3HR-1 harboring an EBV genome in which the EBV nuclear
antigen-2 (EBNA-2) has been deleted [76]. For comparison we
included the BJAB and Ramos cell lines which had previously
been converted to EBV-positive by infection with the EBV
genome originating from the P3HR-1 cell line, BJAB/EBV and
Ramos/EBV [98,100]. In addition, two B cell lines were included.
A human EBV-immortalized B cell line ND1, established from an
MS patient (kind gift from M. Sospedra) and the EBV-producing
B95-8 cotton-top marmoset cell line [77]. EBV DNA was
quantified using serial dilutions of Namalwa DNA (human
Burkitt’s lymphoma cell line containing 2 EBV genome copies
per cell, kindly provided by Regina Feederle) as reference for a
standard curve [75]. All cell lines (mycoplasma free as confirmed
by PCR) were maintained in RPMI 1640 medium supplemented
with 10% fetal calf serum and 1% penicillin-streptomycin in 5%
CO2 at 37uC.
TTV genomes
Thirty full-length TTV genomes were isolated in our laboratory
from 4 brain samples [67], the majority differing in their genome
Figure 3. Quantification of EBV-genomes and -replication. Real-time qPCR in the EBV positive cell lines transfected with TTV-HD14c (day 14
post-transfection) was applied to determine the EBV genome copies per cell, as well as EBV replication as measured by gp350/220 mRNA.
doi:10.1371/journal.pone.0032160.g003
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or consequence of these rearrangements in TT viruses is to date
not known [52,67]. We therefore selected 2 full-length genomes
originating from one brain sample for the transfection assays. The
ORF1 of TTV-HD14b (accession number FR751464) is fused
with the last 37 nt of ORF4 and part of the control region,
whereas TTV-HD14c (acc. no. FR751465) ORF1 is fused to
ORF5. Viral genomes were released from the pCR2.1 vector
construct (Invitrogen) and purified after separation by gel
electrophoresis (PeqLab Biotechnologies) and prior to transfection
of cells.
Transfection of cells and DNA/RNA processing
Transfection of 2 mg TTV-DNA into 5610
6 cells was
performed by using electroporation (Nucleofector II transfection
device, Amaxa Biosystems) and the Nucleotransfection kit V (cat#
vco-101 Amaxa Biosystems) and following protocols recom-
mended by the manufacturer for each respective cell type.
Transfection efficiency was controlled for by parallel transfections
with the plasmid pmaxGFP (Amaxa Biosystems). Negative controls
of each cell line with and without nucleofector solution were
included. Cells were transfected for harvesting on days 3, 7 and 10,
whereas transfected cells harvested at days 14, 17 and 21 were
passaged from transfected cultures for day 7, 10 and 14,
respectively. Cells were passaged at 7 day intervals and fresh
medium added when cells became too dense during this interval.
Transfection assays were performed in parallel by 2 of us (S.B. and
C.W.). Cultures were harvested on days 3, 7, 10, 14, 17 and 21
after transfection at an average density of 1–1,5610
6/ml and total
DNA and RNA isolated. Total DNA was extracted using phenol-
chloroform-isoamylalcohol [65] and subjected to DpnI (Fermen-
tas) digestion to remove input DNA used for transfection. Total
RNA was isolated from the transfected cells using the RNeasy mini
kit (Qiagen, Hilden, Germany). All RNA samples were treated
with DNaseI (Promega) to remove any residual DNA. The quality
of the RNA samples was checked by running the samples in a 1%
agarose gel.
PCR amplification of full-length TTV genomes
In order to investigate whether replication of the transfected
TTV-HD14b and TTV-HD14c occurred in the tested cell lines,
the genomic DNA isolated from all transfected cell lines was
further subjected to long-PCR amplification using TaKaRa LA
Taq enzyme (TAKARA BIO INC) and back-to-back primers. The
specific primers used for each individual TTV type are
documented in Table 1. The reaction was performed as follows:
initial denaturation for 1 min at 94uC, followed by 30 cycles of
30 s at 94uC, 1 min at 68uC (TTV-HD14b) or 1 min at 65uC
(TTV-HD14c) and 4 min at 72uC, followed by final elongation at
72uC for 10 min.
TTV and EBV detection by real-time quantitative PCR
Two sets of primers and the respective hydrolysis probes were
designed on the TTV-HD14b and TTV-HD14c genomic region
spanning nucleotide 1 to 430 (identical between isolates). Primers
and probes for both TTV-HD14b and TTV-HD14c were
obtained from Biomers.net. The two sets (qP31F-qP133R-
qP113Pr and qP326F-qP430R-qP396Pr) were separated by 192
nucleotides. Genomic DNA samples (100 ng in 5 ml) were
amplified in triplicate, each in a total volume of 20 ml containing
12.5 ml Taqman Universal master mix (Applied Biosystems), 0.5 ml
forward primer (10 mM), 0.75 ml reverse primer (20 mM), 0.63 ml
59FAM-39TAMRA-labelled probe (10 mM) and 0.62 ml water.
Reaction mixtures were amplified for 40 cycles (15 s at 95uC and
1 min at 60uC) after an initial activation of the DNA polymerase
for 10 min at 95uC. Fluorescent signals were detected in an ABI
7300 sequence detection system (Applied Biosystems). Results for
each time point (day 3, 7, 10, 14, 17 and 21) were standardized
against the amplification of TTV-HD14b and TTV-HD14c in the
EBV-negative BJAB cell line and expressed as fold change values.
DNA samples obtained from untransfected cells, as well as non-
template controls (NTC) were included in each reaction plate.
Data normalization was performed using the HMBS (hydro-
xymethylbilane synthase) housekeeping gene reported to share the
same specificity in both human and cotton-top tamarin B95-8 cell
lines [101]. Beacon designer 7.9 software was used for the design
of the Taqman assay for HMBS, selecting a homologous region
between the human and cotton-top tamarin genome. Validation of
the primers and probes and assay optimization were performed as
described previously [67]. Amplification reactions of HMBS were
performed in 25 ml volumes, containing 12.5 ml Taqman Univer-
sal master mix (Applied Biosystems), forward and reverse primers
0.75 ml each (10 mM), 0.75 ml5 9FAM-39TAMRA-labelled probe
(10 mM) and 5.25 ml water. The AmpliTaq Gold DNA Polymerase
was activated at 95uC for 10 min prior to amplification through 40
cycles (15 s at 95uC and 1 min at 60uC) during which fluorescent
signals were measured.
EBV DNA was quantified by targeting the BALF1 gene [75] in
the EBV positive cell lines. Genomic DNA samples (2 ng) in
triplicates were used for the reaction and NTC included in each
reaction plate. Primers and probes used to detect EBV DNA are
listed in Table 1. Quantification of EBV DNA in each cell line was
calculated against a standard curve generated by serial dilutions of
Namalwa DNA (2 copies of EBV DNA per cell) as previously
described [75].
EBV activity/replication was measured by quantifying mRNA
production of a 200 bp fragment of the EBV envelope
glycoprotein gene gp350/220 [79]. Primers and a hydrolysis
probe used are listed in Table 1. The RNA samples (5 ng) from the
transfected cells were amplified using a one step RT-qPCR
protocol (Applied Biosystems). Briefly, the RT-qPCR mixture
contained: 12.0035 mml of Taqman Fast Virus 1-Step Master Mix,
1.5 ml each of forward and reverse primers (10 mM), 1.5 mlo f
59FAM-39TAMRA-labelled probe (10 mM), 28 ml water and 5 ml
RNA. An initial reverse transcription step (5 min at 50uC), was
followed by RT inactivation/initial denaturation (20 s at 95uC).
Reaction mixtures were subsequently amplified for 40 cycles (15 s
at 95uC and 1 min at 60uC). Negative controls included NTC and
samples without reverse transcriptase. Fluorescent signals were
detected using an ABI 7300 sequence detection system (Applied
Biosystems). EBV gp350/220 gene expression was quantified using
an external RNA calibration standard which was generated as
follows: The EBV late envelope glycoprotein gp350/220 gene was
transcribed from B95-8 cellular RNA with SuperScript II reverse
transcriptase (Invitrogen) using specific primers containing restric-
tion sites for BamHI and EcoRI (Table 1). The resulting 200 bp
cDNA amplicon was cloned into the pSPT18 vector (SP6/T7
Trancription Kit, Roche) as described previously [79]. Sequence
analysis verified the sequence. The cDNA-containing plasmid was
linearized with EcoRI prior to subsequent in vitro transcription
using SP6 RNA polymerase (SP6/T7 Trancription Kit, Roche).
The size and quality of this transcript were determined by
denaturing RNA electrophoresis. Serial dilutions (5-fold) of this
200 bp gp350/220 transcript in 5 ng BJAB RNA (EBV negative)
in DNase/RNase free water were used to calibrate the EBV
gp350/220 gene expression. Standards were stored in aliquots at
270uC for no longer than 1 week and each aliquot was used once.
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TTV-HD14b and TTV-HD14c amplification in the BJAB cell
line (EBV-negative) was used as a calibrator to compare TTV
amplification between cell lines. For these analyses the mean DDCt
was derived in each experiment and the 95% confidence interval
for mean calculated. These values were converted to fold changes.
Comparisons between TTV-HD14b and TTV-HD14c amplifica-
tion levels (fold changes) in each of Ramos (EBV-negative) and
Ramos/EBV cell lines were performed by t-test.
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